Tested treatment for hepatitis B-related liver cancer after immunotherapy
Part of Cancer, Digestive system clinical trials.
This trial studies whether the ALSS treatment is safe and effective for people with hepatitis B-related hepatocellular carcinoma who recently received immune checkpoint inhibitors. It may help improve outcomes for certain liver-related complications after immunotherapy, based on how their liver tests look.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You have chronic hepatitis B, shown by positive hepatitis B tests (surface antigen or viral DNA).
- You have liver cancer (hepatocellular carcinoma) and your last immunotherapy dose was within the past 3 months.
- Your hepatitis B viral load is under 2000 IU/mL.
- Your blood tests show significant liver stress (AST/ALT and bilirubin are very high) and blood clotting is affected (INR over 1.5).
- You have enough platelets (above 50×10^9/L) and no bile duct swelling caused by tumor growth.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This study tests a combination of two treatments for advanced liver cancer (hepatocellular carcinoma): a bile acid supplement called tauroursodeoxycholic acid plus an immunotherapy drug (a PD-1/PD-L1 inhibitor) that helps your immune system fight the cancer. The goal is to see if this combination is safe and effective in people who have not yet had any whole-body cancer treatment.
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
Hear when a new Immune-Mediated Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.